CDK1 and neoplasm: Thus, we propose that the ability of cediranib, but not bevacizumab, to inhibit multiple kinases and to dephosphorylate the G2/M gatekeeper cdc2 results in G2/M checkpoint abrogation, premature entry of tumor cells with damaged DNA into mitosis, and cell death through mitotic catastrophe.